Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
It is through our dedication to advancing global healthcare that we have become one of the largest pharmaceutical companies in the world, driven by the energy and passion of our people.
Our position and growth has been achieved through a broad offering of medicines, vaccines and integrated healthcare solutions, with sales reaching €37.054billion in 2015.
At Sanofi we care about healthcare; because healthcare matters
Historically we've concentrated on working to alleviate and cure common diseases - both chronic and acute in nature (focusing on cardiovascular medicine, thrombosis, oncology, internal medicine, metabolic disorders, diseases of the central nervous system and vaccines). Whilst this work remains important, we never rest on our laurels, and with one of the biggest referenced portfolios of products in the world, we are constantly looking at ways to improve and advance.
So where does our future lie? We aim to continue to deliver new medicines to meet the needs of patients by being a partner of choice to those committed to improving people's health across our 3 key business units; Diabetes and Cardiovascular; Sanofi Genzyme, which covers Oncology, Immunology, Multiple Sclerosis and Rare Disease and; General Medicine, which includes our Established Product portfolio, Consumer Health Care and Generics. Globally, we've committed to increasing our annual R&D investment from €5 to €6billion by 2020, which amounts to 14% of sales. At the end of July 2016, the R&D pipeline contained 44 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 14 are in Phase III or have been submitted to the regulatory authorities for approval. Approximately 50% of these projects come from collaborations and partnerships; . this supports our ambition to challenge the status quo, ever-searching for innovative healthcare solutions to benefit both customers and patients.